Bruce Records, MD
General Practice · Greenwood, INNPI 1740252667
Payments from drug & device makers
Across 122 payments — averaging $11.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$328
- Novo Nordisk$159
- GSK$138
- Takeda Pharmaceuticals U.S.A., Inc.$105
- Lilly USA, LLC$84
- Novartis$76
- plus $507 from 16 others
What the payments were for
- Food & beverage$1,391100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $328 |
| Novo Nordisk | 17 | $159 |
| GSK | 12 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $105 |
| Lilly USA, LLC | 6 | $84 |
| Novartis | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| Sunovion Pharmaceuticals Inc. | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $55 |
| Sanofi-aventis U.S. LLC | 4 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| AstraZeneca | 3 | $36 |
| Teva Pharmaceuticals USA, Inc. | 3 | $33 |
| Amgen | 2 | $29 |
| Nalpropion Pharmaceuticals LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,397 in reported general payments places this provider in the 85th percentile of 1,558 general practice providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 92 | $106,288 |
| TrulicityDulaglutide | 57 | $105,133 |
| EliquisApixaban | 69 | $95,963 |
| OzempicSemaglutide | 75 | $93,794 |
| JardianceEmpagliflozin | 43 | $62,669 |
| OxycontinOxycodone Hcl | 23 | $35,433 |
| JanuviaSitagliptin Phosphate | 17 | $25,049 |
| XareltoRivaroxaban | 19 | $19,331 |
| FarxigaDapagliflozin Propanediol | 14 | $18,971 |
| RybelsusSemaglutide | 11 | $18,258 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $17,829 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $15,135 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 294 | $10,114 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $8,676 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $84 | $211,422149 claims |
| Novo NordiskOzempic, Rybelsus | $159 | $112,05286 claims |
| Boehringer IngelheimJardiance | $11 | $62,66943 claims |
| AstraZenecaFarxiga, Symbicort | $36 | $25,10727 claims |
| MerckJanuvia | $12 | $25,04917 claims |
| Johnson & JohnsonXarelto | $12 | $19,33119 claims |
| GSKBreo Ellipta | $138 | $17,82929 claims |
| AbbVieSynthroid | $328 | $1,85042 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,558 general practice providers in Indiana.
Other general practice in Greenwood
- Ramandeep KaurGreenwood$5K
- Tina GermanWarsaw$260K
- Kenneth TroutmanHuntingburg$124K
- Roger JonesClinton$78K
- Daniel KlauerGranger$45K
- William FloraElkhart$39K
- Ryan HolmesFort Wayne$33K
- Samuel CoreyFort Wayne$27K
- Kara WulffMuncie$23K
- Gary WalkerFishers$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.